# Interests Register

## Hypertension in adults Advisory Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Role with NICE</th>
<th>Type of interest</th>
<th>Description of interest</th>
<th>Relevant dates</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Wierzbicki</td>
<td>Guideline Chair; Consultant in Metabolic Medicine/Chemical Pathology</td>
<td>Direct financial</td>
<td>Received travel and accommodation expenses from the PCSK9 Forum (an independent lipids educational institute funded indirectly by the pharmaceutical industry amongst other sources)</td>
<td>Upon appointment</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct non-financial</td>
<td>International Steering committee – STAREE trial of lipid-lowering in the elderly</td>
<td>Upon appointment</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct non-financial</td>
<td>Site clinical lead investigator for lipid-lowering drugs: Amgen (evolocumab); Merck Sharp &amp; Dohme (anacetrapib); Akcea (volanesorsen)</td>
<td>Upon appointment</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indirect financial</td>
<td>Clinical registry lead (Chiesi; lipoprotein lipase GENIALL registry)</td>
<td>Upon appointment</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indirect financial</td>
<td>Currently, holds role of Investigator on clinical trials for a number of companies in the field of lipids. Does not receive direct payment, all payments are made to his hospital trust.</td>
<td>27/09/2017</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct non-financial</td>
<td>Talk on diagnosis of familial hypercholesterolaemia: South-West London CVD group (unpaid). Symposium sponsored by educational grant from Sanofi/Amgen.</td>
<td>05/03/2018</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Name</td>
<td>Title and Position</td>
<td>Interests</td>
<td>Start Date</td>
<td>End Date</td>
<td>Specificity</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------</td>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Ann Elizabeth Denver</td>
<td>Hypertension Nurse (Diabetes), Whittington Health NHS Trust</td>
<td>Direct non-financial&lt;br&gt;Member of the British Hypertension society and member of association of medical prescribers</td>
<td>27/09/2017</td>
<td></td>
<td>Specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Mark Glover</td>
<td>Consultant Hypertension Specialist Physician, MRC Clinician Scientist and Associate Professor, University of Nottingham and Nottingham University Hospitals NHS Trust</td>
<td>Indirect non-financial&lt;br&gt;As clinical scientist with the MRC researching in the following areas:&lt;br&gt;- Thiazide Induced Hyponatraemia (a side effect of low salt concentration in the blood caused by thiazide diuretics)&lt;br&gt;- The genetics of a rare inherited form of hypertension called ‘Gordon syndrome’&lt;br&gt;The medical research council funds all research.</td>
<td>27/09/2017</td>
<td></td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td></td>
<td>Direct non-financial</td>
<td>Member of the British hypertension society.</td>
<td></td>
<td>27/09/2017</td>
<td>Specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Financial Type</td>
<td>Details</td>
<td>Date</td>
<td>Status</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>Judith Magowan</td>
<td>Practice nurse, Okehampton Surgery; Associate lecturer, Plymouth University</td>
<td>Indirect</td>
<td>The University of Nottingham’s outpatient clinic is run by Circle, a private company, that administers services on behalf of the NHS</td>
<td>16/11/2018</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Terry McCormak</td>
<td>Principal in General Practice, Whitby Practice</td>
<td>Direct</td>
<td>Nil return.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>non-financial</td>
<td>Secretary and Trustee of the British Hypertension Society 2012 - 2016 Fellow of the British and Irish Hypertension Society</td>
<td>At application</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct</td>
<td>McCormack T, Carlisle J, Anderson S, Hartle A. Preoperative blood pressure measurement: what should GPs be doing? Br J Gen Pract. May 2016. VOL 66. Number 646,230-1</td>
<td>05/2016</td>
<td>At application</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indirect</td>
<td>Research grants from Amgen, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Leo Pharma, Pfizer and the National Institute for Health Research. These research payments are paid to Whitby Group Practice, of which I am a variable 6-7% shareholder. They support the employment of two research nurses and one research administrator.</td>
<td>At application</td>
<td></td>
</tr>
<tr>
<td>Interests</td>
<td>Details</td>
<td>Date of application</td>
<td>Date of declaration</td>
<td>Action Status</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td><strong>Direct financial</strong></td>
<td>Speaker fees from Bayer (anti-coagulation therapies) and Merck Sharpe &amp; Dohme (lipid therapies). Travel grants for scientific meetings from Amgen and Bayer. None of these relate to hypertension. They are all declared on the ABPI disclosures website.</td>
<td></td>
<td>At application</td>
<td>Non-specific. No action other than the process of open declaration</td>
<td></td>
</tr>
<tr>
<td><strong>Direct non-financial</strong></td>
<td>I am a committee member of the NICE Venous Thromboembolism Update Guideline Committee.</td>
<td>12/2017</td>
<td>08/01/2018</td>
<td>Non-specific. No action other than the process of open declaration</td>
<td></td>
</tr>
<tr>
<td><strong>Indirect financial</strong></td>
<td>I gave a talk on atrial fibrillation management at a Primary Care Cardiovascular Society meeting. The Whitby Group Practice research fund received my speaker fee from Boehringer Ingelheim.</td>
<td></td>
<td>08/01/2018</td>
<td>Non-specific. No action other than the process of open declaration</td>
<td></td>
</tr>
<tr>
<td><strong>Direct financial</strong></td>
<td>I received a travel and accommodation grant from MSD to attend the European Society of Cardiology meeting in Barcelona from 25 to 30 Aug 2017.</td>
<td>08/2017</td>
<td>02/11/2018</td>
<td>2017</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td><strong>Direct non-financial</strong></td>
<td>I am a committee member of the NICE Perioperative Care Medicine Guideline Committee.</td>
<td>2018</td>
<td>28/02/2018</td>
<td>2020 (expected)</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td><strong>Direct financial</strong></td>
<td>I received a fee from AstraZeneca for advising them about a new treatment for raised potassium.</td>
<td>2018</td>
<td>28/02/2018</td>
<td>Specific. Partial exclusion. Declare and withdraw from drafting recommendations on step 4 treatment. The committee member will remain in the</td>
<td></td>
</tr>
<tr>
<td>Interest Type</td>
<td>Name</td>
<td>Description</td>
<td>Date</td>
<td>End Date</td>
<td>Comment</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
<td>-------------</td>
<td>------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>Indirect financial</td>
<td>The Whitby Group Practice Research Fund</td>
<td>has received a payment from Roche for work on a guideline to manage high blood pressure caused by treatments for cervical and ovarian cancer.</td>
<td>06/04/18</td>
<td>10/10/2018</td>
<td>Ongoing Specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Indirect financial</td>
<td>The Whitby Group Practice Research Fund</td>
<td>has received additional payments from Sanofi and Weight Watchers for research activities.</td>
<td>23/08/18</td>
<td>10/10/2018</td>
<td>05/09/18 Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Financial Interests</td>
<td>Date</td>
<td>Date of Exclusion</td>
<td>Nature of Partial Exclusion</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>------------</td>
<td>-------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Irene McGill</td>
<td>Lay member</td>
<td>Nil return.</td>
<td>26/09/18</td>
<td>10/10/2018</td>
<td>Specific. Partial exclusion. Declare and withdraw from drafting recommendations on step 4 management. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.</td>
</tr>
<tr>
<td>Richard McManus</td>
<td>Professor of Primary Care, Primary Care Health Sciences, University of Oxford; General practitioner, Honorary Consultant in Primary Care, Oxford Health</td>
<td>Direct non-financial. Omran (a BP monitor manufacturer) have supplied electronic BP monitors for the TASMINH4 trial for which I am Chief Investigator.</td>
<td>Upon appointment</td>
<td>26/09/18</td>
<td>Specific. Partial exclusion. Declare and withdraw from drafting recommendations on monitoring of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.</td>
</tr>
<tr>
<td>NHS Foundation Trust</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------</td>
<td>------------------------</td>
<td>------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>I am a member of the European Society of Hypertension / European Society of Cardiology Hypertension Guideline Advisory Group.</td>
<td>Upon appointment</td>
<td>room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this paper.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>I chair the British Hypertension Society BP Monitoring working group.</td>
<td>Upon appointment</td>
<td>Specific. No action other than the process of open declaration.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Interests Register
Hypertension in adults advisory committee
| Direct financial | I am a General Practitioner Principal in Oxford and a shareholder in a company that runs a GP practice in Birmingham where I was previously based. | Upon appointment | Non-specific. No action other than the process of open declaration |

The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.
<table>
<thead>
<tr>
<th>Interests</th>
<th>Author(s)</th>
<th>Year</th>
<th>Specific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct non-financial</td>
<td>Albasri, A., O’Sullivan, J. W., Roberts, N. W., Prinjha, S., McManus, R. J., &amp; Sheppard, J. P.</td>
<td>2017</td>
<td>Specific. Partial exclusion. Declare and withdraw from drafting recommendations on diagnosis of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.</td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>Tompson, A. C., Grant, S., Greenfield, S. M., McManus, R. J., Fleming, S., Heneghan, C. J., Ward, A. M. Patient use of blood pressure self-screening facilities in general practice waiting rooms: a qualitative study in the UK. Br J Gen Pract, 2017. 67(660), e467-e473. doi:10.3399/bjgp17X690881</td>
<td>2017</td>
<td>Upon appointment</td>
</tr>
<tr>
<td>Interests</td>
<td>Name(s)</td>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>Franssen, M., Farmer, A., Grant, S., Greenfield, S., Heneghan, C., Hobbs, R., McManus, R. J. Telemonitoring and/or self-monitoring of blood pressure in hypertension (TASMINH4): protocol for a randomised controlled trial. BMC Cardiovasc Disord, 2017 17(1), 58. doi:10.1186/s12872-017-0494-5</td>
<td>2017, Upon appointment, Specific. Partial exclusion. Declare and withdraw from drafting recommendations on monitoring of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.</td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Interest Type</td>
<td>Name and Details</td>
<td>Date</td>
<td>Action</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------</td>
<td>------</td>
<td>--------</td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>Billingsley Kaambwa, Stirling Bryan, Emma Frew, Emma Bray, Sheila Greenfield, Richard J McManus; on behalf of the TASMINH2</td>
<td>2016</td>
<td>Upon appointment</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09/2016</td>
<td>Upon appointment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>withdraw from drafting recommendations on monitoring of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest</td>
<td>Description</td>
<td>Specific Questions</td>
<td>Date</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>--------------------</td>
<td>------</td>
</tr>
</tbody>
</table>
| Direct non-financial | Stevens SL, Wood S, Koshiaris C, Law K, Glasziou P, Stevens RJ, McManus RJ. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ. 2016 Aug 9;354:i4098. doi: 10.1136/bmj.i4098. | 08/2016 | Upon appointment | hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic. | Specific. Partial exclusion. Declare and withdraw from drafting recommendations on diagnosis and monitoring of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to
<p>| Direct non-financial | Hodgkinson J, Koshiaris C, Martin U, Mant J, Heneghan C, Hobbs FR, McManus RJ. Accuracy of monitors used for blood pressure | 03/2016 | Upon appointment | Specific. Partial exclusion. Declare and |</p>
<table>
<thead>
<tr>
<th>Interests Register</th>
<th>Hypertension in adults advisory committee</th>
</tr>
</thead>
</table>

### Direct non-financial

| Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, Virdee S, Greenfield S, Hobbs FD. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke-Blood Pressure) randomised controlled trial. BMJ. 2016 Feb 24;352:i708. doi: 10.1136/bmj.i708. | 02/2016 | Upon appointment | Non-specific. No action other than the process of open declaration |


<table>
<thead>
<tr>
<th>Nature of Financial Interest</th>
<th>Description</th>
<th>Date</th>
<th>Additional Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct financial</td>
<td>Conducts research mostly about blood pressure, monitoring and management.</td>
<td>27/09/2017</td>
<td>Specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Indirect financial</td>
<td>Has received blood pressure monitoring equipment by manufacturer (Omron UK), not a monetary gift, but in support of trial work being undertaken.</td>
<td>27/09/2017</td>
<td>Specific. Partial exclusion. Declare and withdraw from drafting recommendations on monitoring of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this.</td>
</tr>
<tr>
<td>Type</td>
<td>Description</td>
<td>Date</td>
<td>Notes</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>Member of the hypertension society.</td>
<td>27/09/2017</td>
<td>Specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>On the European society for hypertension guideline development group.</td>
<td>27/09/2017</td>
<td>09/2018 Specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Indirect financial</td>
<td>Received grants for research on essential hypertension, pregnancy and antihypertensive withdrawal in over 80s from the NIHR and on self-monitoring /management of BP after stroke from the Stroke Association.</td>
<td>27/09/2017</td>
<td>Specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Indirect financial</td>
<td>NIHR NSPCR grant to examine the impact of the 2011 NICE guidance in a primary care dataset.</td>
<td>27/09/2017</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Indirect financial</td>
<td>Co-investigator on another trial of a digital intervention including self-monitoring and for a trial of spironolactone in CKD.</td>
<td>27/09/2017</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>Over the summer, I was involved in an ARC bid which involves work on self-monitoring in collaboration with a technology partner called: <a href="https://www.sensynehealth.com">https://www.sensynehealth.com</a> As part of this I met with the CEO Lord Drayson and discussed the potential for their help in turning our telemonitoring intervention into a commercial app. He has written a letter</td>
<td>08/2018</td>
<td>05/09/2018 Specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Interests Register</td>
<td>of support for the Oxford ARC including pledging matched funding (in kind) I have no personal financial interest nor do I expect to have one (funds will go to the university)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial</td>
<td>Omboni S. J Clin Hypertens (Greenwich). 2018 Jul;20(7):1128-1132. doi: 10.1111/jch.13305. PMID: 30003701</td>
<td>Declare and withdraw from drafting recommendations on monitoring of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.</td>
<td></td>
</tr>
<tr>
<td>Interest Type</td>
<td>Description</td>
<td>Date</td>
<td>Action</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Interest</td>
<td>Nature</td>
<td>Description</td>
<td>Date Action Taken</td>
</tr>
<tr>
<td>----------</td>
<td>--------</td>
<td>-------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Direct</td>
<td>non-financial</td>
<td>Qualitative process study to explore the perceived burdens and benefits of a digital intervention for selfmanaging high blood pressure in Primary Care in the UK. Morton K, Dennison L, Bradbury K, Band RJ, May C, Ranery J, Liile P, McManus RJ, Yardley L. BMJ Open. 2018 May 8;8(5):e020843. doi: 10.1136/bmjopen-2017-020843. PMID: 29739782</td>
<td>05/2018</td>
</tr>
<tr>
<td>Direct</td>
<td></td>
<td>Using the Person-Based Approach to</td>
<td>05/2018</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>Direct</td>
<td>Authors' reply re: Inadequate safety reporting</td>
<td>09/2018</td>
<td>16/11/2018</td>
</tr>
<tr>
<td>Interest</td>
<td>Description</td>
<td>Author(s)</td>
<td>Journal</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>Lucy Pollock</td>
<td>Consultant Geriatrician, Direct financial</td>
<td>Dermal sponsored talk on 26 September 2017 about care of complex frail elderly. Talk briefly</td>
<td>27/09/2017</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Financial Relationship</td>
<td>Action</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Taunton and Somerset NHS</td>
<td>Partner at Wolstanton Medical Centre. Wolstanton Medical Centre is a</td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td>Foundation Trust</td>
<td>Keele University research practice.</td>
<td>Direct non-financial</td>
<td>application</td>
</tr>
<tr>
<td>Mark Shapley</td>
<td>Fellow of the Royal College of General Practitioners</td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>application</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td>Alison Warren</td>
<td>Speaker fee from Bayer x2 (anticoagulation for atrial fibrillation)</td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td>February and June 2017</td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Direct financial</td>
<td>At</td>
</tr>
</tbody>
</table>

Interests Register
Hypertension in adults advisory committee

32 of 45
### Interests Register

#### Hypertension in adults advisory committee

<table>
<thead>
<tr>
<th>Direct financial non-specific</th>
<th>Sponsorship to attend ESC Cardiology 2015 (Daichhi Sankyo)</th>
<th>At application</th>
<th>Non-specific. No action other than the process of open declaration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct financial</td>
<td>Received fees for speaking on lipids and anti-coagulation.</td>
<td>27/09/2017</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Direct financial</td>
<td>I received an educational sponsorship from Novartis to attend the Annual British Society of Heart failure Meeting in London November 2017.</td>
<td>11/12/2017</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Direct financial</td>
<td>I attended the Thrombosis Management Conference sponsored by Bayer. This covered travel, accommodation for 2 nights and conference attendance in line with ABPI regulations.</td>
<td>22/06/18 11/07/2018 24/06/18</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
<tr>
<td>Direct financial</td>
<td>Educational grant from Novartis to attend the British Society of Heart Failure annual conference (London)</td>
<td>29/11/18 16/11/18 30/11/18</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
</tbody>
</table>

**Bryan Williams, resigned from the committee on 10 October 2018.**

<p>| Chair of Medicine, University College London (UCL) (HEFCE-tenured); Director, National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre | Direct financial | In my role as an academic clinician, with a global profile in hypertension, I am often asked to provide advice as a consultant and/or lead trial steering committees for new drug or device development for the treatment of hypertension. These drugs or devices are not yet, or likely to be available, for clinical use for some time (and may never be) for the treatment of hypertension and will not be relevant to the deliberations of this guideline committee. | At application | Non-specific. No action other than the process of open declaration |
| Direct financial | Consultant fee received directly. | Vascular Dynamics (USA) – consultancy (personal) on the development of early phase trial/s for the evaluation of an endovascular stent for the treatment of resistant hypertension. Global CI for a phase II trial. | At application | Non-specific. No action other than the process of open declaration |
| Direct financial | Novartis – Consultancy / steering committee (personal) designing an early phase clinical trial for the evaluation of a new chemical entity for the treatment of resistant hypertension. | At application | Non-specific. No action other than the process of open declaration |
| Direct financial | I am also invited to deliver educational lectures at CME accredited scientific and clinical symposia at international congresses on the subject of hypertension, that are supported by honoraria and expenses either directly or indirectly (via industry sponsorship of the international congress). Daiichi Sankyo, Novartis, Servier, Pfizer – Honorarium and expenses (personal) for Hypertension masterclass lectures and invited speaker at major international scientific symposia on the broad subject of hypertension. | At application | Specific. Partial exclusion. Declare and withdraw from drafting recommendations on pharmacological treatment of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee |</p>
<table>
<thead>
<tr>
<th>Direct non-financial</th>
<th>Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from Advance-on. Diabetes Care in press 2017-11-15</th>
<th>11/2017</th>
<th>At application</th>
<th>Non-specific. No action other than the process of open declaration regarding this topic.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct non-financial</td>
<td>Accuracy of cuff-measured blood pressure. Systematic reviews and meta-analyses. J Am Coll Cardiol. 70: 572-586; 2017.</td>
<td>2017</td>
<td>At application</td>
<td>Specific. Partial exclusion. Declare and withdraw from drafting recommendations on diagnosis of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.</td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>A Universal standard for the validation of blood pressure measuring devices: Association for the advancement of medical instrumentation/ European society of hypertension/ International organization for</td>
<td>2017</td>
<td>At application</td>
<td>Specific. Partial exclusion. Declare and withdraw from drafting</td>
</tr>
<tr>
<td>Direct non-financial</td>
<td>Application of non-invasive central aortic pressure assessment in clinical trials: Clinical experience and value. Artery Research 17: 1-15; 2017</td>
<td>2017</td>
<td>At application</td>
<td>Non-specific. No action other than the process of open declaration</td>
</tr>
</tbody>
</table>
### Interests Register

**Hypertension in adults advisory committee**

<table>
<thead>
<tr>
<th>Type</th>
<th>Name</th>
<th>Date</th>
<th>Status</th>
<th>Action</th>
</tr>
</thead>
</table>
<pre><code>                        |      |                                  | 08/2017                  | At application                                                      | Non-specific. No action other than the process of open declaration |
</code></pre>
|                            | Lip GYH, Coca A, Kahan T, Boriani G, Manolis AS, Olsen MH, Oto A, Potpara TS, Steffel J,  
                            |      |                                  | 06/2017                  | At application                                                      | Non-specific. No action other than the process of open declaration |
                            |      |                                  |                          |                                                                       |                                                                       |
|                            | Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm  
                            |      |                                  |                          |                                                                       |                                                                       |
|                            | Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society  
                            |      |                                  |                          |                                                                       |                                                                       |
|                            | (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion  
<p>| | | | | |
|      |                                  |                          |                                                                       |                                                                       |
|      |                                  | 09/2017                  | At application                                                      | Non-specific. No action other than the process of open declaration |</p>
<table>
<thead>
<tr>
<th>Interests Register</th>
<th>Hypertension in adults advisory committee</th>
<th>Direct non-financial</th>
<th>Direct non-financial</th>
</tr>
</thead>
</table>

### Direct non-financial


06/2017 At application Specific. Partial exclusion. Declare and withdraw from drafting recommendations on monitoring of hypertension. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic.

### Direct non-financial


05/2017 At application Specific. Partial exclusion. Declare and withdraw from drafting recommendations
11. Review.

<table>
<thead>
<tr>
<th>Interest Type</th>
<th>Interest Description</th>
<th>Date</th>
<th>At Application</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct</td>
<td>Interests</td>
<td>Author(s)</td>
<td>Year</td>
<td>Action</td>
</tr>
<tr>
<td>--------</td>
<td>-----------</td>
<td>---------------------------------------------------------------------------</td>
<td>------</td>
<td>--------</td>
</tr>
<tr>
<td>financial</td>
<td>financial</td>
<td>Atkins, E. R., Hirakawa, Y., Salam, A., Woodward, M., Cooper, M., Hamet, P., Rodgers, A. (2017). Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials. JOURNAL OF HYPERTENSION, 35 (6), 1318-1325. doi:10.1097/HJH.0000000000001287</td>
<td>2017</td>
<td>At application</td>
</tr>
<tr>
<td>financial</td>
<td>financial</td>
<td>Relypsa – Consultancy / steering committee (personal) designing and overseeing the conduct of a phase 3 trial of a potassium binding agent in patients treated for resistant</td>
<td>28/02/2018</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Type of Conflict</td>
<td>Declaration Details</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------------------------------</td>
<td>------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Parijat De</td>
<td>Consultant Physician In Diabetes, Endocrinology and Lipid Metabolism</td>
<td>Direct financial</td>
<td>I have received speaker fees for educational talks in diabetes from most companies but not from any pharmaceutical companies regarding hypertension. Upon appointment. Non-specific. No action other than the process of open declaration.</td>
<td></td>
</tr>
<tr>
<td>Christopher Floyd</td>
<td>Trainee</td>
<td>Direct financial</td>
<td>I am a Director of Cranworth Medical Ltd, which is a mobile application development agency specialising in software for healthcare. The company has no interests related to hypertension. Upon appointment. Non-specific. No action other than the process of open declaration.</td>
<td></td>
</tr>
</tbody>
</table>
**GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.